Carisma Therapeutics (NASDAQ:CARM – Get Rating) is one of 994 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Carisma Therapeutics to similar businesses based on the strength of its analyst recommendations, dividends, risk, profitability, valuation, institutional ownership and earnings.
This is a breakdown of current ratings for Carisma Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Carisma Therapeutics Competitors||4351||15335||41777||733||2.63|
Carisma Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 76.99%. As a group, “Pharmaceutical preparations” companies have a potential upside of 103.02%. Given Carisma Therapeutics’ rivals higher probable upside, analysts plainly believe Carisma Therapeutics has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
Earnings and Valuation
This table compares Carisma Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Carisma Therapeutics||$3.53 million||-$19.88 million||-2.83|
|Carisma Therapeutics Competitors||$8.54 billion||$225.66 million||-3.74|
Carisma Therapeutics’ rivals have higher revenue and earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Carisma Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Carisma Therapeutics Competitors||-3,252.01%||-239.66%||-35.23%|
Risk and Volatility
Carisma Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Carisma Therapeutics’ rivals have a beta of 0.84, suggesting that their average stock price is 16% less volatile than the S&P 500.
Carisma Therapeutics rivals beat Carisma Therapeutics on 7 of the 13 factors compared.
About Carisma Therapeutics
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.